Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.Hope S. Rugo, Kathleen I. Pritchard, Martine Piccart et al.|Journal of Clinical Oncology|2012Cited by 4
Clinical management and resolution of stomatitis in BOLERO-2.Alejandra Perez, Howard A. Burris, Hope S. Rugo et al.|Journal of Clinical Oncology|2013Cited by 3